Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | NPY4R | P50391 | 9/20 | 0.38 |
| ▸ | NPY1R | P25929 | 6/20 | 0.38 |
| ▸ | NPY2R | P49146 | 5/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | FURIN | P09958 | 7/20 | 0.38 |
| ▸ | TFPI | P10646 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23335231 | 0.91 | SIRT6 (0.47) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL23335237 | 0.87 | TLR2 (0.45) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL23335144 | 0.86 | FURIN (0.47) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL23335236 | 0.85 | SIRT6 (0.44) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL30447227 | 0.82 | SIRT6 (0.47) | SIRT6SIRT1SIRT5FURIN | |
| SCHEMBL23335233 | 0.82 | SIRT6 (0.47) | SIRT6SIRT1SIRT5FURIN | |
| SCHEMBL29626768 | 0.81 | SIRT6 (0.57) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL31024641 | 0.81 | SIRT6 (0.57) | SIRT6SIRT1SIRT5NPY4RNPY1R | |
| SCHEMBL23335238 | 0.78 | SLC15A2 (0.49) | SIRT1NPY4RNPY2R | |
| SCHEMBL23335143 | 0.76 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128743-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | PAUL SCHERRER INSTITUT (CH) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128743-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | TGM3, TGM2, TGM1 | SIRT6 3856/4885SIRT1 4244/4885SIRT5 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.